Cross-Study Meta-Analysis of Blood Transcriptomes in Type 2 Diabetes
Authors:
- Aleksandr A. TkachenkoATAleksandr A. Tkachenko
- Ziravard N. TonyanZTZiravard N. Tonyan
- Yulia A. NasykhovaYNYulia A. Nasykhova
- Yury A. BarbitoffYBYury A. Barbitoff
- Iaroslav N. RenevIRIaroslav N. Renev
- Maria M. DanilovaMDMaria M. Danilova
- Anastasiia A. BasipovaABAnastasiia A. Basipova
- Olga B. GlavnovaOGOlga B. Glavnova
- Dmitrii E. PolevDPDmitrii E. Polev
- Sergey V. ChepanovSCSergey V. Chepanov
- Sergey A. SelkovSSSergey A. Selkov
- Nikita V. GolovkinNGNikita V. Golovkin
Open Access
- 15 December 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (24) , 12046
Abstract
Type 2 diabetes (T2D) is a chronic metabolic disorder with an estimated prevalence of over 422 million individuals affected globally. Since the advent of genomics, numerous studies have been conducted to elucidate T2D pathogenetic mechanisms and define genetic loci affecting T2D susceptibility. Transcriptomic studies, including bulk and single-cell RNA sequencing, play an important role both in discerning molecular mechanisms of the disease and in identifying potential T2D biomarkers. In this study, we performed bulk RNA-seq of whole blood of nine T2D patients and nine control subjects and performed meta-analysis of these data with seven publicly available blood RNA-seq datasets of T2D patients. Our analysis showed that the changes in the gene expression between different studies show very low concordance; moreover, a substantial number of differentially expressed genes (DEGs) was identified in only three out of eight datasets, with only five DEGs—FBLN2, TPCN1, PC, SHANK1, and PLD4—identified in all three of those datasets. Nevertheless, cross-study meta-analysis identified a broad set of 2065 DEGs, including 713 genes that have not been identified in any of the source studies. These genes showed a significant enrichment of GO terms indicating neutrophil activation and proliferation and included several genes that have not been implicated in type 2 diabetes previously. Taken together, our study highlights challenges associated with biomarker discovery from blood transcriptomics in T2D and suggests novel genes that may be considered as such biomarkers.Keywords
Funding Information
- Ministry of Science and Higher Education of the Russian Federation (075-15-2025-478)
This publication has 99 references indexed in Scilit:
- Biomarker signatures distinguish diabetic retinopathy and diabetic nephropathyDiabetology International, 2025
- Multi‐omics reveals different signatures of obesity‐prone and obesity‐resistant miceiMetaOmics, 2025
- FBLN2 is associated with basal cell markers Krt14 and ITGB1 in mouse mammary epithelial cells and has a preferential expression in molecular subtypes of human breast cancerBreast Cancer Research and Treatment, 2024
- Neutrophils and their role in the aetiopathogenesis of type 1 and type 2 diabetesDiabetes/Metabolism Research and Reviews, 2021
- Association of MTHFR C677T polymorphism and type 2 diabetes mellitus (T2DM) susceptibilityMolecular Genetics & Genomic Medicine, 2019
- Global trends in diabetes complications: a review of current evidenceDiabetologia, 2018
- In vivo evidence of enhanced di-methylation of histone H3 K4 on upregulated genes in adipose tissue of diabetic db/db miceBiochemical and Biophysical Research Communications, 2011
- Decreased levels of metabolic enzymes in pancreatic islets of patients with type 2 diabetesDiabetologia, 2009
- The role of pyruvate carboxylase in insulin secretion and proliferation in rat pancreatic beta cellsDiabetologia, 2008
- The Insulin Receptor Substrate IRSp53 Links Postsynaptic shank1 to the Small G-Protein cdc42Molecular and Cellular Neuroscience, 2002